HK1205457A1 - N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer - Google Patents

N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer Download PDF

Info

Publication number
HK1205457A1
HK1205457A1 HK15106028.6A HK15106028A HK1205457A1 HK 1205457 A1 HK1205457 A1 HK 1205457A1 HK 15106028 A HK15106028 A HK 15106028A HK 1205457 A1 HK1205457 A1 HK 1205457A1
Authority
HK
Hong Kong
Prior art keywords
cancer
amg
cells
tumor
treatment
Prior art date
Application number
HK15106028.6A
Other languages
English (en)
Chinese (zh)
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1205457(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HK1205457A1 publication Critical patent/HK1205457A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15106028.6A 2009-09-11 2013-01-16 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer HK1205457A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
US241527P 2009-09-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK13100715.9A Addition HK1173655B (en) 2009-09-11 2010-09-09 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK13100715.9A Division HK1173655B (en) 2009-09-11 2010-09-09 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
HK1205457A1 true HK1205457A1 (en) 2015-12-18

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106028.6A HK1205457A1 (en) 2009-09-11 2013-01-16 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Country Status (34)

Country Link
US (1) US20120028917A1 (cg-RX-API-DMAC7.html)
EP (2) EP2818170B1 (cg-RX-API-DMAC7.html)
JP (1) JP5851403B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120082896A (cg-RX-API-DMAC7.html)
CN (1) CN102869361A (cg-RX-API-DMAC7.html)
AU (1) AU2010292225C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008325A2 (cg-RX-API-DMAC7.html)
CA (1) CA2773838C (cg-RX-API-DMAC7.html)
CL (1) CL2012000640A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120171A (cg-RX-API-DMAC7.html)
DK (1) DK2475368T3 (cg-RX-API-DMAC7.html)
EA (1) EA020526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2528485T3 (cg-RX-API-DMAC7.html)
HK (1) HK1205457A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150104T1 (cg-RX-API-DMAC7.html)
HU (1) HUE024568T2 (cg-RX-API-DMAC7.html)
IL (1) IL218569A0 (cg-RX-API-DMAC7.html)
MA (1) MA33658B1 (cg-RX-API-DMAC7.html)
ME (1) ME02048B (cg-RX-API-DMAC7.html)
MX (1) MX2012003041A (cg-RX-API-DMAC7.html)
NZ (1) NZ598758A (cg-RX-API-DMAC7.html)
PE (1) PE20120895A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500504A1 (cg-RX-API-DMAC7.html)
PL (1) PL2475368T3 (cg-RX-API-DMAC7.html)
PT (1) PT2475368E (cg-RX-API-DMAC7.html)
RS (1) RS53807B1 (cg-RX-API-DMAC7.html)
SG (1) SG179102A1 (cg-RX-API-DMAC7.html)
SI (1) SI2475368T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500028B (cg-RX-API-DMAC7.html)
TN (1) TN2012000110A1 (cg-RX-API-DMAC7.html)
TW (1) TW201121956A (cg-RX-API-DMAC7.html)
UA (1) UA107675C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011031842A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202472B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Hrp-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG11201604517WA (en) 2013-12-03 2016-07-28 Amgen Inc Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
WO2017181087A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304266A1 (en) * 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EA018128B1 (ru) * 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Also Published As

Publication number Publication date
HK1173655A1 (en) 2013-05-24
ZA201202472B (en) 2012-12-27
US20120028917A1 (en) 2012-02-02
CA2773838C (en) 2016-05-31
HRP20150104T1 (xx) 2015-03-13
EP2818170B1 (en) 2018-12-05
MX2012003041A (es) 2012-06-27
PL2475368T3 (pl) 2015-05-29
KR20120082896A (ko) 2012-07-24
EA020526B1 (ru) 2014-11-28
PT2475368E (pt) 2015-02-10
AU2010292225B2 (en) 2012-12-13
CL2012000640A1 (es) 2012-09-21
CR20120171A (es) 2012-08-09
EP2818170A1 (en) 2014-12-31
SMT201500028B (it) 2015-03-05
EA201270383A1 (ru) 2013-04-30
MA33658B1 (fr) 2012-10-01
AU2010292225C1 (en) 2013-06-27
CA2773838A1 (en) 2011-03-17
ES2528485T3 (es) 2015-02-10
WO2011031842A1 (en) 2011-03-17
ME02048B (me) 2015-05-20
EP2475368B1 (en) 2014-12-17
IL218569A0 (en) 2012-05-31
AU2010292225A1 (en) 2012-04-12
NZ598758A (en) 2013-12-20
DK2475368T3 (en) 2015-03-09
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
HUE024568T2 (hu) 2016-02-29
JP5851403B2 (ja) 2016-02-03
CN102869361A (zh) 2013-01-09
UA107675C2 (xx) 2015-02-10
JP2013504582A (ja) 2013-02-07
TN2012000110A1 (en) 2013-09-19
RS53807B1 (sr) 2015-06-30
PH12012500504A1 (en) 2015-04-29
TW201121956A (en) 2011-07-01
SG179102A1 (en) 2012-04-27
PE20120895A1 (es) 2012-08-19
BR112012008325A2 (pt) 2017-08-29

Similar Documents

Publication Publication Date Title
EP2475368B1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
JP6433085B2 (ja) がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン
KR20170017932A (ko) Mdm2 억제제의 간헐적 투여
EP3493848B1 (en) Heterocyclic diamidines
US20190262319A1 (en) Novel methods for treating cancer
JP2016535014A (ja) がんの処置のための医薬の組合せ
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
EP2890374B1 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
HK1173655B (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
EP3070092B1 (en) 3-phenyl-thiazolo[3,2-a]benzimidazole derivatives as aldehyde dehydrogenase 1 (aldh-1) modulators for the treatment of breast cancer or leukemia, and for manipulating cultured aldh-1 positive breast cancer or leukemia cells
CN112999236B (zh) 乌本苷用于治疗脑干胶质瘤的用途
WO2010085462A1 (en) Method for treating triple negative breast cancer